Electron Reliability Offsets Neutron Delay but Dilution Risks Persist for Rocket Lab

What happened

Rocket Lab's Electron rocket continues to demonstrate reliability with 19 launches in 2026, supporting a growing backlog, but the company's medium-lift Neutron program remains delayed with its first launch pushed into 2027 after a January 2026 tank rupture and an October 2026 timeline reset. The core operating business is expanding, with first-half 2026 revenue up 63% year-over-year to $434.4 million and a $2.356 billion backlog, yet the company still posted a $49.3 million net loss in Q2 2026 and burned $134.4 million in operating cash during the first half. The proposed $8 billion Iridium acquisition, intended to add high-margin satellite telecom cash flows, has increased financing demands and led to substantial share dilution via ATM equity issuance of roughly $1.944 billion. The stock has corrected sharply, now trading around $52.7 per share (down 22.6% over the observed period) with a $30.4 billion market cap that embeds significant re-rating expectations from Neutron and Iridium. In this context, Electron's reliability provides a foundation of steady demand, but it is not sufficient to offset the valuation and execution risks tied to Neutron milestones and Iridium integration.

Implication

The stock's current level implies a high probability of successful Neutron commercialization and Iridium closing on favorable terms, but given the operational cash burn, repeated schedule slippage, and dilution from ATM issuance, the risk-reward is unattractive for new money. Disciplined investors should wait for either a pullback toward the $42 attractive entry or a filing-backed Neutron launch date and sequential cash burn improvement before adding.

Thesis delta

The thesis remains unchanged: Rocket Lab's core small-launch business is executing, but the investment case is gated by Neutron schedule credibility and Iridium financing dilution. The recent article confirms Electron reliability and backlog strength, but does not alter the primary risks. Therefore, the WAIT rating and valuation framework remain appropriate.